|
|
| |
| A knock on the head after 65 keeps counting |
| A fall is rarely just a fall. Researchers in Ontario went looking for what happens next. They pulled the health records of more than 260,000 adults past 65 and followed them for up to 17 years. |
| Let me explain how they built it. Every person who turned up with a head injury was paired with someone who had not — same age, same sex, same odds of being sick in other ways. Then the team watched who got a dementia diagnosis. One knock was the only real difference between the pairs. |
| They pulled away early. And they never came back. Even beyond the five-year mark, the injured group still carried a 56% higher dementia risk. In the first five years it ran higher still. The head does not file a knock and forget it. |
| |
Over half start with a fall at home. Past 85, roughly one in three went on to a dementia diagnosis. |
|
| I could be wrong here. This is a look back at records, not a trial. People who fall are often unsteady already. And unsteadiness has its own quiet road to dementia. So read the number as a warning light, not a verdict. |
| Still, the practical part is yours today. I urge you to treat a fall as a brain event, not a bruise. Get the rug that slides taken up. Get the hallway lit. Get your eyes checked, and ask your doctor whether your blood pressure drops when you stand. |
| Yu Qing Huang & Jennifer Watt, St. Michael’s Hospital, University of Toronto · Canadian Medical Association Journal, October 2025 |
|
|
|
|
| |
| Stir a spoon of plant fibre into breakfast |
| This one costs about a pound a week. Two cheap plant fibres, inulin and fructo-oligosaccharide, sit on the shelf in most chemists. You cannot digest either one. The bacteria living in your gut can, and the helpful ones multiply on it. |
| A London team tested it properly. Researchers at King’s College London recruited 36 pairs of twins, all past 60. One twin got the fibre daily. The other got a dummy powder, and nobody knew which was which. Twins make a tidy comparison. The genes on both sides of the table match. |
| The fibre twins came out ahead. It took twelve weeks. They scored better on a picture-and-place learning test, one doctors watch as an early Alzheimer’s marker. Their reaction times and processing speed moved too. Muscle strength did not budge at all. Both groups did the same exercises. |
| So here is how to run it yourself. |
| The Protocol |
| When |
| Once a day, stirred into breakfast — porridge, yoghurt or a glass of water |
| Duration |
| 12 weeks, the length the trial ran |
| Rules |
| Start on half a dose for the first week. Buy the plain powder, not a blend with sweeteners in it. Keep eating ordinary fibre as well — beans, oats, skins on. Expect some wind for a few days while the gut settles. |
| |
| Keep the size of it in view. Seventy-two people, twelve weeks, better test scores. Not a dementia result. The powder is cheap. The downside is a windy week. I urge you to give it the full twelve. |
|
|
|
|
|
|
|
| A sniff of dark chocolate bought 18 extra reps |
| Smell takes the shortest road in. A team at the University of Malaya used that. Twenty-three fasted men did leg extensions while sniffing dark chocolate, milk chocolate or plain water. The dark scent added about 18 repetitions. The milk scent added about 9. The work felt no harder, and hunger dropped too. Small, young and male. So hold it loosely, and try it before your next set. |
| University of Malaya · Frontiers in Physiology, 2026 |
|
|
| Whole grains pay off in a narrow band |
| More is not always better. Helda Tutunchi and colleagues pooled 87 trials covering more than 6,500 people. The gains clustered between 60 and 100 grams a day. Call it porridge, a sandwich on brown bread and a serving of brown rice. In that band, blood pressure, blood fats and blood sugar all eased. So did waist size and one marker of inflammation. The trials averaged eight weeks. They measured markers, not heart attacks. |
| Tabriz University of Medical Sciences · European Heart Journal, September 15 2026 |
|
|
| Your nerve fibres are beaded, not smooth |
| Textbooks drew them as smooth cables. Shigeki Watanabe and his team at Johns Hopkins froze brain tissue fast instead of soaking it in chemicals. The cables came out looking like strings of tiny pearls. The beads are not decoration. After heavy firing they swelled and stayed swollen for half an hour. The signal changed speed with them. Most of this work is in mice. Nobody yet knows where healthy beading ends and disease begins. |
| Johns Hopkins Medicine · Neuron, February 2026 |
|
|
|
|
| |
| The approved drugs have a narrow door. They are for people caught early, and everyone else is turned away at it. So look at three trials by the door they are trying to open instead. One starts before a single symptom. One works in the middle of the illness. One takes on advanced disease, where nothing at all is approved. |
|
| Treating people who still feel perfectly fine |
| AHEAD 3-45 starts earliest. It enrolls adults aged 55 to 80 who think and work normally. What they share is plaque on a brain scan. Half the study takes people whose plaque is already high. The other half takes people whose plaque is only creeping up, and tests a lower dose. Treatment runs four years. Screening has closed, and the answer is years away. |
| Alzheimer’s Clinical Trial Consortium with the National Institute on Aging and Eisai · four-year treatment period, enrolment complete |
|
|
| Cleaning the blood to draw plaque out of the brain |
| This one uses no new molecule. Blood is drawn off and the fluid part is swapped for fresh albumin. That is the carrier protein that ferries things around the body. Then the cells go back in. Albumin holds plaque protein, so replacing it pulls a little more out of circulation. In the AMBAR trial, 496 patients in Spain and the United States went through it. The moderate group declined 61% less over 14 months. One trial, six years old. Still not approved anywhere. |
| Grifols · results published 2020, a confirming trial still needed |
|
|
| Trying to rebuild connections late in the illness |
| Bryostatin-1 comes from a sea creature. It grows on harbour pilings. The drug flips a switch inside the brain cell. That switch tells the cell to grow new connections. A small trial funded by the National Institutes of Health gave it to about 100 people with advanced Alzheimer’s. Six months of treatment. The people not already taking one older memory drug held their ground. Some of that held for months after the drug stopped. Small numbers and an odd subgroup. A bigger trial is the only way to know. |
| Synaptogenix · Phase 2, published 2023 |
|
|
